Oral semaglutide reduces heart failure hospitalization, urgent heart failure visits, or cardiovascular death in patients with type 2 diabetes and a history of heart failure
Current assessment
Synthesis pending
Confidence
Not assessed
Supporting evidence (0)
Nothing recorded on this side
Contradicting evidence (0)
Nothing recorded on this side
Discussion (0)
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.